Deferasirox dominates deferoxamine for iron overload

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.665, 2012-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deferasirox a strong contender for iron overload in all ages

Inpharma, Vol. 1, Iss. 1476, 2005-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Deferasirox: A Review of its Use in the Management of Transfusional Chronic Iron Overload

By Yang Lily P.H. Keam Susan J. Keating Gillian M.

Drugs, Vol. 67, Iss. 15, 2007-01 ,pp. : 2211-2230

Adis International

Access to resources Recommend Favorite

Deferasirox: a guide to its use in transfusional chronic iron overload

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 24, Iss. 2, 2008-02 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

By Cappellini MD Taher A

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2391-2402

Informa Healthcare

Access to resources Recommend Favorite

Oral deferasirox may be an effective iron chelator in patients with thalassaemia and transfusional iron overload

Inpharma, Vol. 1, Iss. 1387, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite